Avalo Therapeutics, Inc.
NASDAQ:AVTXBiotechnology
-$0.34 today
- Market cap
- $387.41M
- Beta
- 0.82
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$4.21
Volume 1.58M
Average 1.61M
AVTX EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Avalo Therapeutics, Inc.NASDAQ: AVTX
EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026
EPS (Diluted) remains negative
Q1 FY2026 EPS (Diluted) was -$0.98, compared with -$1.25 a year earlier. Trailing-twelve-month EPS (Diluted) was -$5.83.
Context
- EPS (Diluted) grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 8 analysts of -$2.42 (+58.6%) for the fiscal year ending Dec 2026, a step up from the -79.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.98-32.4% QoQ
- Last fiscal yearDec 2025
- -$5.84-79.1% YoY
- LTMMar 2026
- -$5.83-124.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +21.6% | +69.6% | +48.0 pp |
| 1 year | -79.1% | +58.6% | +137.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (5.84) USD
- Year-over-year change
- -79.1%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (5.84) | -79.1% |
| FY2024 | 2024-12-31 | (3.26) | +97.1% |
| FY2023 | 2023-12-31 | (113.58) | +89.3% |
| FY2022 | 2022-12-31 | (1,062.65) | +54.4% |
| FY2021 | 2021-12-31 | (2,330.66) | — |
EPS (Diluted) vs competitors
How AVTX compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Diluted) is compared through growth and rates rather than absolute size.
- Its year-over-year change of -124.1% is the 8th highest of 10, against a peer median of +39.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $2.66 USD | +153.8% | — | |
| LTM Mar 2026 | -$0.56 USD | +59.7% | — | |
| LTM Mar 2026 | -€0.61 EUR | +19.6% | — | |
| LTM Mar 2026 | -$0.87 USD | +60.7% | — | |
| LTM Mar 2026 | -$1.08 USD | +78.0% | — | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | FY2024 | -€1.26 EUR | -306.5% | — |
| LTM Jun 2026 | -$2.17 USD | +13.5% | — | |
| LTM Sep 2026 | -$2.74 USD | -166.0% | — | |
| LTM Mar 2026 | -$5.83 USD | -124.1% | — | |
| LTM Mar 2026 | -$5.98 USD | +39.0% | — | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — |
| Peer median (excluding AVTX) | — | +39.0% | — | |
Competitors are the stored peer set for AVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 5.4M | 18.05M | 1.92M | 441K | 59K |
| Cost of Revenue | 1.49M | 3.43M | 1.28M | (366K) | 0 |
| Gross Profit | 3.91M | 14.62M | 640K | 807K | 59K |
| Gross Margin | 72.4% | 81.0% | 33.3% | 183.0% | 100.0% |
| Research & Development | 59.84M | 31.31M | 13.78M | 52.08M | 50.08M |
| Selling, General & Admin | 24.66M | 20.71M | 10.3M | 17.24M | 22.9M |
| Operating Expenses | 86.04M | 52.06M | 27.99M | 69.32M | 72.98M |
| Depreciation & Amortization | 1.66M | 166K | 158K | 169K | 344K |
| EBITDA | (80.5M) | (37.29M) | (23.29M) | (34.85M) | (77.75M) |
| EBITDA Margin | -1491.2% | -206.6% | -1210.3% | -7901.6% | -131779.7% |
| Operating Income | (82.13M) | (37.44M) | (27.35M) | (68.51M) | (72.93M) |
| Operating Margin | -1521.6% | -207.4% | -1421.6% | -15535.6% | -123601.7% |
| Interest Income | 0 | 0 | 0 | 3.32M | 4.35M |
| Interest Expense | 2.39M | 4.17M | 3.42M | 0 | 0 |
| Other Income / Expenses | (2.41M) | (4.19M) | (4.18M) | 33.5M | (5.17M) |
| Income Before Tax | (84.55M) | (41.63M) | (31.53M) | (35.02M) | (78.09M) |
| Pre-Tax Margin | -1566.2% | -230.6% | -1638.8% | -7939.9% | -132362.7% |
| Income Tax Expense | (196K) | 28K | 14K | 114K | 165K |
| Net Income | (84.38M) | (41.66M) | (31.54M) | (35.13M) | (78.26M) |
| Net Margin | -1563.1% | -230.8% | -1639.5% | -7965.8% | -132642.4% |
| EPS (Basic) | (2,330.66) | (1,062.65) | (113.58) | (4.32) | (5.84) |
| EPS (Diluted) | (2,330.66) | (1,062.65) | (113.58) | (3.26) | (5.84) |
| Weighted Avg Shares | 36.19K | 39.2K | 277.73K | 8.13M | 13.4M |
| Weighted Avg Shares (Diluted) | 36.19K | 39.2K | 277.73K | 10.78M | 13.4M |
Avalo Therapeutics, Inc.
NASDAQ:AVTX
Intrinsic Alpha fair value
Locked
Current Price
$6.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.